WO2011111384A1 - Composition transdermique contenant un agent thérapeutique pour la maladie de parkinson - Google Patents

Composition transdermique contenant un agent thérapeutique pour la maladie de parkinson Download PDF

Info

Publication number
WO2011111384A1
WO2011111384A1 PCT/JP2011/001381 JP2011001381W WO2011111384A1 WO 2011111384 A1 WO2011111384 A1 WO 2011111384A1 JP 2011001381 W JP2011001381 W JP 2011001381W WO 2011111384 A1 WO2011111384 A1 WO 2011111384A1
Authority
WO
WIPO (PCT)
Prior art keywords
transdermal composition
composition according
ergot
transdermal
ropinirole
Prior art date
Application number
PCT/JP2011/001381
Other languages
English (en)
Japanese (ja)
Inventor
山崎啓子
Original Assignee
株式会社メドレックス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社メドレックス filed Critical 株式会社メドレックス
Publication of WO2011111384A1 publication Critical patent/WO2011111384A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Definitions

  • the present invention relates to a transdermal composition containing a therapeutic agent for Parkinson's disease. More particularly, the present invention relates to a transdermal composition containing ropinirole hydrochloride or pramipexole hydrochloride which is a dopamine D 2 receptor agonist.
  • Parkinson's disease As motor function diseases, intractable neurological diseases such as Parkinson's disease, restless leg syndrome (RLS), and essential tremor are known, and several therapeutic agents including L-Dopa are used. Recently, ropinirole and pramipexole to selectively stimulate dopamine D 2 receptor system of striatal postsynaptic is promising. Parkinson's disease is characterized by deformation and loss of neurons in the midbrain substantia nigra, which produces dopamine, a neurotransmitter that is important for the realization of motor function.
  • Parkinson's disease is characterized by deformation and loss of neurons in the midbrain substantia nigra, which produces dopamine, a neurotransmitter that is important for the realization of motor function.
  • RLS Restless Legs Syndrome
  • tremor is the most frequent involuntary tremor in the hand and head, and is said to be due to an abnormality in the motor control area of the brain.
  • ropinirole and pramipexole which are promising therapeutic agents for Parkinson's disease, have the following characteristics.
  • the hydrochloride salt of ropinirole (ie 4- [2- (dipropylamino) ethyl] -1,3-dihydro-2H-indol-2-one) and pramipexole (ie (S) -2-amino-4,5,6) , 7-tetrahydro-6-propylaminobenzothiazole) is a selective anti-dopamine D 2 receptor agonist with a non-ergot structure and is associated with Parkinson's disease, restless leg syndrome (RLS), It is useful for treatment such as war (Patent Document 1).
  • ropinirole hydrochloride is usually determined to be a starting dose of 0.75 mg / day and a maintenance dose of 3-9 mg / day for adults, and can be administered orally in three divided doses per day.
  • Non-Patent Document 1 The half-life in blood of healthy adults when administered orally is as short as about 5 hours, suggesting a large first-pass effect in the liver. Pramipexole hydrochloride can be treated at a dose lower than that of ropinirole, but the half-life in blood of healthy adults when administered orally is short, about 6 hours.
  • a transdermal administration method is suitable as an administration method with less influence on the living body side. That is, transdermal administration was considered useful as an administration method in order to maintain a constant blood concentration for a long time and to reduce side effects.
  • transdermal administration in the case of transdermal administration, the transfer rate of the drug into the blood is slower than oral administration.
  • a therapeutic agent for Parkinson's disease a faster effect is desired as well as drug persistence. Therefore, a transdermal preparation of ropinirole and pramipexole needs to have a high initial permeation rate as well as drug durability.
  • it is a long-term continuous transdermal administration, it is indispensable to reduce the safety and burden on the skin.
  • a salt of a drug formed by a combination of an acid and a base such as hydrochloride is usually highly water-soluble in protonated form, and has a skin permeability. It is known not to show. Therefore, in many cases, a technique is used in which the composition is free base and has skin permeability. Jamyson et al. Also confirmed the permeability after ropinirole was made the free base by bringing the composition to pH 7-8.5 because ropinirole hydrochloride did not find skin permeability in the experiment. (Patent Document 3). However, ropinirole and pramipexole are basic compounds and are unstable and easily discolored at pH 7 or higher. Further, considering the safety to the skin, the pH range (pH 7 to 8.5) in which the above preparation has good absorbability was not desirable.
  • the present inventor conducted a search for a liquid agent that enhances the skin permeability of non-ergot anti-dopamine D 2 receptor agonists (ropinirole and pramipexole) using the in vitro rat skin permeability test as an index.
  • ropinirole and pramipexole non-ergot anti-dopamine D 2 receptor agonists
  • percutaneous absorbability can be improved by preparing a microdispersed solution of ropinirole. That is, ropinirole hydrochloride is partially neutralized in an aqueous solution to form a free base (free form), a hydrophobic solvent and a surfactant are added, mixed and stirred, and micelles partially containing ropinirole are mixed.
  • the micelle aqueous solution was diluted and stirred with a polyhydric alcohol to prepare a colloidal solution in which the micelles were small and uniformly dispersed.
  • the colloidal solution was shown to have excellent ropinirole transdermal absorbability. Further investigation revealed that the transdermal absorbability was better when the pH of the colloidal solution was 4-6.
  • the above-described colloidal solution which is a composition for transdermal use of the present invention, has been shown to exhibit a clear Tyndall phenomenon and excellent transdermal absorbability as the average particle size decreases.
  • the transdermal composition of the present invention is uniformly dispersed by forming micelles (ropinirole, hydrophobic solvent and surfactant) having an average particle diameter of 1 ⁇ m or less in a water-polyhydric alcohol solvent. It is what. In order to exhibit excellent transdermal absorbability, it is further desirable that the average particle diameter of the micelle is as small as 100 nm or less.
  • the tertiary amine residue of the ropinirole side chain in the micelle partially protrudes into the water-polyhydric alcohol solvent. It is thought that it is protonated.
  • minute micelles with such a structure come into contact with the skin, they are protonated, so they are likely to adhere to the skin surface, and the micelle's hydrophobic solvent acts as a transdermal absorption enhancer, resulting in intercellular lipids in the epidermis. It has been considered to promote percutaneous absorption of ropinirole by softening. The same is thought to have occurred with pramipexole.
  • the present inventor completed the present invention based on the above findings.
  • the gist of the present invention is as follows.
  • Non-ergot anti-dopamine D 2 receptor agonist, micelle composed of hydrophobic solvent and surfactant is uniformly dispersed in water-polyhydric alcohol solvent, pH 4-6
  • the nonionic surfactant is a polyoxyethylene sorbitan fatty acid ester.
  • the transdermal composition according to (6), wherein the polyoxyethylene sorbitan fatty acid ester is polysorbate 20, polysorbate 60, polysorbate 65, or polysorbate 80.
  • the transdermal composition according to (12), wherein the higher fatty acid is a saturated or unsaturated fatty acid having 4 to 18 carbon atoms.
  • the transdermal composition according to (12), wherein the higher fatty acid is an unsaturated fatty acid having 4 to 18 carbon atoms.
  • the transdermal composition according to (14), wherein the unsaturated fatty acid having 4 to 18 carbon atoms is oleic acid.
  • non-ergot anti dopamine D 2 receptor agonist is contained 0.1 to 10 percent as the hydrochloride salt, transdermal composition according to the above (1).
  • a non-ergot anti-dopamine D 2 receptor agonist hydrochloride is defined as 1, with a molar ratio of hydrophobic solvent of 0.4 to 2 times mol and surfactant of 0.1 to 0.4 times mol.
  • non-ergot anti dopamine D 2 receptor agonist transdermal composition containing, a) After adding water to the non-ergot anti-dopamine D 2 receptor agonist hydrochloride to dissolve it, the pH is adjusted to about 6.5 with a diluted aqueous alkali metal hydroxide solution, b) Stir vigorously after adding a hydrophobic solvent to the aqueous solution. c) A surfactant is added to the above solution and stirred further to obtain a uniform milky suspension.
  • the transdermal compositions of the present invention emulsion solution prepared with non-ergot anti dopamine D 2 receptor agonist and a hydrophobic solvent and a surfactant is uniformly dispersed in a solvent of water and a polyhydric alcohol It is a colloidal solution having a pH of 4-6.
  • the transdermal composition of the present invention was able to achieve the desired excellent skin permeability and high initial permeability. As a result, an excellent therapeutic effect can be achieved by administering the transdermal composition of the present invention against Parkinson's disease, restless leg syndrome (RLS), essential tremor and other neurological movement disorders.
  • non-ergot anti-dopamine D 2 receptor agonist of the present invention is a drug that stimulates dopamine D 2 receptor, produces acetylcholine, and treats Parkinson's disease. This is one of the two types of non-ergot alkaloids.
  • ergot anti-dopamine D 2 receptor agonists are cabergoline, pergolide, bromocriptine, and non-ergot anti-dopamine D 2 receptor agonists refer to ropinirole, pramipexole, and talipexol.
  • ropinirole hydrochloride is marketed as Requip
  • pramipexole hydrochloride is marketed as biciflor
  • talipexol hydrochloride is marketed as domine, both as therapeutic agents for Parkinson's disease.
  • the “hydrophobic solvent” of the present invention is, for example, isopropyl isostearate, methyl stearate, butyl stearate, butyl myristate, ethyl linoleate, isopropyl linoleate, ethyl olive oleate, myristyl myristate, cetyl isoctanate, myristine Non-octyldodecyl acid, diisopropyl adipate, cetyl palmitate, retinol palmitate, methyl laurate, methyl myristate, methyl caproate, methyl palmitate, isopropyl myristate, isopropyl palmitate, diethyl sebacate, diethyl adipate, etc.
  • Lower fatty acid monohydric alcohol esters such as oleic acid triglyceride, Panacet 800, Panacet 810 and other medium chain fatty acid triglycerides such as olive oil and palm oil Vegetable oils, N- methyl-2-pyrrolidone derivative of pyrrolidone, liquid paraffin, can be mentioned crotamiton.
  • Preferred examples include crotamiton, diethyl sebacate, and medium chain fatty acid triglycerides.
  • the “surfactant” of the present invention refers to a substance having a hydrophilic group and a hydrophobic group, which has a function of forming micelles and uniformly mixing a polar substance and a nonpolar substance.
  • Surfactants are classified into anionic surfactants, nonionic surfactants, zwitterionic surfactants, and cationic surfactants because of their chemical structure.
  • synthetic surfactants and natural surfactants depending on the production method.
  • Preferred surfactants are nonionic surfactants for synthetic surfactants and lecithin for natural surfactants.
  • nonionic surfactant of the present invention is, for example, monooleyl polyoxyethylene sorbitan (for example, polysorbate 20, polysorbate 60, polysorbate 65, polysorbate 80, etc.), sorbitan monolaurate, sorbitan monopalmitate, sorbitan sesquioxide.
  • monooleyl polyoxyethylene sorbitan for example, polysorbate 20, polysorbate 60, polysorbate 65, polysorbate 80, etc.
  • sorbitan monolaurate for example, polysorbate 60, polysorbate 65, polysorbate 80, etc.
  • sorbitan monopalmitate for example, sorbitan sesquioxide.
  • Polyoxyethylene sorbitan fatty acid esters such as oleate, polyoxyethylene castor oil derivatives, polyoxyethylene hydrogenated castor oil, glycerin fatty acid esters such as glycerin monostearate and sorbitan monooleate, sorbitan fatty acids such as sorbitan monostearate and sorbitan sesquioleate Esters, polyoxyethylene higher alcohol ethers such as polyoxyethylene ether ether, polyoxyethylene alkylphenol, polyoxyethylene Oxypropylene copolymer (e.g., Pluronic, etc.) and the like.
  • a preferable example is polysorbate 80.
  • the “lecithin” of the present invention refers to a lipid product containing a phospholipid such as phosphatidylcholine. Lecithin is further classified according to what is used as a raw material. Those using egg yolk as a raw material are called “yolk lecithin”, and those using soybean as a raw material are called “soy lecithin”. In addition, including purification methods, it is also classified into plant lecithin, fractionated lecithin, egg yolk lecithin, enzyme-treated lecithin, enzyme-decomposed lecithin, hydrogenated lecithin and the like. Preferable examples include egg yolk lecithin.
  • polyhydric alcohol solvent examples include dihydric alcohols such as ethylene glycol, propylene glycol and 1,3-butylene glycol, and trihydric alcohols such as glycerin.
  • dihydric alcohols such as ethylene glycol, propylene glycol, and 1,3-butylene glycol. More preferred are propylene glycol and 1,3-butylene glycol.
  • the “micelle” of the present invention is an aggregate of a hydrophobic solvent, ropinirole, and a nonionic surfactant, which is spherical in a water-polyhydric alcohol solvent with the hydrophobic portion facing inward and the hydrophilic portion facing outward.
  • the side chain tertiary amine residue of ropinirole can be protonated and transferred to the hydrophilic portion by appropriately adjusting the liquidity (pH) of the water-polyhydric alcohol solvent.
  • the “particle diameter” in the present invention means the average particle diameter of the above micelles, and can be measured, for example, with a photon correlation measuring device (manufactured by Sysmex, Zeta Sizer Nano ZS).
  • the preferred particle size is preferably 20 nm to 1 ⁇ m in order to obtain good transdermal absorbability. More preferable examples include 30 to 500 nm. More preferable examples include those having a thickness of 50 to 150 nm.
  • Such minute micelles are referred to as micellized nanoparticles.
  • the “Tyndall phenomenon” of the present invention means that when a red laser beam is applied to a solution in which the micelles of the present invention are uniformly dispersed (colloidal solution), particles in the solution scatter light (Mie scattering), and a single laser beam is emitted. A phenomenon that can be seen. When the laser beam is irradiated and the optical path of the laser can be clearly seen in the solution, it can be said to be a clear Tyndall phenomenon. In addition, when the average particle diameter of the micelle increases and exceeds 1 ⁇ m, the Tyndall phenomenon does not occur, and the whole solution is irregularly reflected. That is, when the average particle diameter of the micelle exceeds 1 ⁇ m, the solution is not transparent and becomes turbid.
  • “Liquid” in the present invention refers to the pH of a transdermal composition (mixed solvent system of water and polyhydric alcohol).
  • the pH is desirably in the range of about 4 to 6, and a pH of about 5 is preferred.
  • the “alkali metal hydroxide” in the present invention refers to lithium hydroxide, sodium hydroxide, and potassium hydroxide, preferably sodium hydroxide and potassium hydroxide.
  • the transdermal composition of the present invention is a liquid, and a suspending agent or thickener, a stabilizer, a buffer, a pH adjuster, a colorant, a fragrance and the like can be added depending on the purpose.
  • Suspensions or thickeners that can be added include gum arabic, ragant, pullulan, locust bin gum, tamarind gum, pectin, xanthan gum, guar gum, carrageenan and other polysaccharides, methylcellulose, carmellose, carmellose sodium, polyvinyl alcohol, polyvinyl Examples include pyrrolidone, acrylic acid copolymer, carboxyvinyl polymer, and the like. Examples of stabilizers that can be added include preservatives and antioxidants.
  • Examples of the preservative include parahydroxybenzoates such as methylparaben and propylparapen, alcohols such as chlorobutanol, pendyl alcohol, and phenylethyl alcohol, thimerosal, acetic anhydride, sorbic acid, and EDTA.
  • Examples of the antioxidant include sodium bisulfite, L-ascorbic acid, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate, tocopherol acetate, dl- ⁇ -tocopherol and the like.
  • Examples of the pH adjuster include lower fatty acids such as acetic acid, lactic acid, citric acid, and oxalic acid, for example, saturated or unsaturated higher fatty acids having 4 to 18 carbon atoms such as butanoic acid, decanoic acid, palmitic acid, oleic acid, and stearic acid. Mention may be made of organic acids such as fatty acids. Preferable examples include higher fatty acids such as decanoic acid, palmitic acid, and oleic acid.
  • Examples of the wetting agent that can be added include polyhydric alcohols such as glycerin, propylene glycol, butylene glycol (1,3-butylene glycol), and sorbitol.
  • mint oil for example, mint oil, l-menthol, camphor, thymol, tocopherol acetate, glycyrrhetinic acid, nonyl acid vanillylamide, pepper extract and the like can be added.
  • pharmaceuticals having other drugs can be added as long as they do not interfere with the effects of the external preparation of the present invention.
  • the additives exemplified above are appropriately selected according to the dosage form of the external preparation of the present invention, These addition amounts are also appropriately selected within the range usually used according to each dosage form.
  • the dosage form of the transdermal composition of the present invention is not particularly limited as long as it can be applied on the basis of a liquid and can be locally administered to the skin.
  • the present invention may be any preparation that can be mixed and impregnated with the liquid preparation of the present invention in a base or matrix such as an ointment, cream, gel, poultice, lotion, aerosol, etc. It can be used as a dosage form of The transdermal compositions of the present invention, depending on the content and dosage form of a non-ergot anti dopamine D 2 receptor agonist, may be administered topically.
  • the amount of the transdermal composition may be selected depending on the content of the non-ergot anti dopamine D 2 receptor agonist, for example, once a day or more than once or continuously used for more than a few days
  • the number of uses can be set according to the pathology of Parkinson's disease.
  • Example 1 Colloid solution composition containing ropinirole hydrochloride as a non-ergot anti-dopamine D 2 receptor agonist.
  • 34 g of water was added to 4 g (13.5 mM) of ropinirole hydrochloride to dissolve it.
  • the pH was adjusted to about 6.5 with 0.01 N sodium hydroxide solution, and 3 g (14.8 mM) of crotamiton was added and stirred.
  • 3 g (about 2.3 mM) of polysorbate 80 was added and stirred again, and then oleic acid was added to adjust the pH to 5.
  • 55 g of propylene glycol was added as a polyhydric alcohol to obtain a uniform dispersion solution.
  • the average particle size of the colloidal solution was about 79 nm as measured by Zetasizer Nano ZS manufactured by Sysmex. Further, the polyhydric alcohol was similarly replaced with butylene glycol as shown in Table 1 to prepare a colloidal solution.
  • the obtained colloidal solution was evaluated for transdermal absorbability by the method of Test Example 1 and listed in Table 1 together with the average particle size result.
  • the average particle diameter of the colloid solution composition was calculated from the particle size distribution of the micelles of FIG. 3 (Experiment No. A) (the average particle diameter of Experiment No. A was 79 nm). Other compositions were measured in the same manner, and the average particle size was calculated.
  • Example 2 Confirmation of Effect of Hydrophobic Solvent
  • Comparative Example 1 a preparation (Comparative Example 1) free from the hydrophobic solvent crotamiton was prepared. That is, as shown in Comparative Example 1 of Table 2, 34 g of water was dissolved in 4 g of ropinirole hydrochloride, and then the pH was adjusted to about 6.5 with 0.01 N sodium hydroxide solution. Thereafter, 3 g of polysorbate 80 was added and stirred, and oleic acid was added to adjust the pH to 5. Next, 55 g of propylene glycol was added to prepare a uniform solution. The particle diameter of the obtained Comparative Example 1 was measured in the same manner as in Example 1. About the comparative example 1, transdermal absorbability was evaluated by the method of the test example 1, and it described in Table 2 with the result of the average particle diameter.
  • the transdermal absorbability of ropinirole was reduced without the hydrophobic solvent.
  • the sample of Comparative Example 1 is an experiment No. Unlike the sample of A, the Tyndall phenomenon was not shown and diffuse reflection was shown. Therefore, a hydrophobic solvent is required to show excellent transdermal absorbability, and it is necessary to form micelles in an aqueous solution. That is, it was found that when a colloidal solution in which micelles containing ropinirole were uniformly dispersed was prepared, the transdermal absorbability of ropinirole was greatly improved.
  • Example 4 Confirmation of effect of water
  • the composition of the present invention is a colloidal solution in which ropinirole and a hydrophobic solvent are uniformly dispersed in a hydrophilic solvent of water and a polyhydric alcohol. Therefore, the presence of water is considered indispensable for forming micelles. Therefore, as shown in Table 4 below, a formulation with no water (Comparative Example 3) was prepared, and the effect of water was evaluated in comparison with the above-described formulation (Experiment No. A, B). For Comparative Example 3, the transdermal absorbability was evaluated by the method of Test Example 1, and the results are shown in Table 4 together with the average particle size results.
  • Example 5 Effect of Surfactant and Hydrophobic Solvent
  • lecithin was used as the surfactant and the effect of the nonionic surfactant was compared. It was.
  • liquid paraffin was used as the hydrophobic solvent, which also served as a comparison with the medium chain fatty acid triglyceride.
  • preparations (Experiment No. E) shown in Table 5 below were prepared and compared with preparations (Experiment No. C) using a nonionic surfactant.
  • the skin permeation amount of ropinirole was evaluated by the method of Test Example 1 and listed in Table 5.
  • Example 6 Nonergot-type anti-dopamine D 2 receptor agonist and effect on transdermal absorbability Ropinirole and pramipexole are taken as non-ergot-type anti-dopamine D 2 receptor agonists according to the method of Example 1.
  • the preparations shown in Table 6 below (Experiment No. E, No. F) were prepared and compared.
  • the skin permeation amounts of ropinirole and pramipexole were evaluated by the method of Test Example 1 and listed in Table 6.
  • a red laser was irradiated to the preparation (Experiment No. F) in Table 6, a Tyndall phenomenon occurred, and a red light path was seen in the solution.
  • the colloid solution preparation of the present invention showed excellent transdermal absorbability with respect to ropinirole and pramipexole.
  • Test Example 1 Evaluation test of transdermal absorbability by Franz cell In order to compare percutaneous absorbability with respect to the samples of Examples A to D and Comparative Examples 1 to 3, 0.7 mL was collected from each sample. Then, a transdermal absorbability evaluation test was performed as follows using a Franz diffusion cell (permeation area: 1 cm 2 , receptor liquid volume: 8 mL) at a test temperature of 32 ° C.
  • Rat skin 6-week-old Wistar rat (male) abdominal skin
  • Receptor solution physiological saline: ethanol (10: 1)
  • Permeabilized drug concentration measurement HPLC method
  • the rat abdominal skin (6-week-old Wistar rat) is sandwiched between vertical diffusion cells (effective diffusion area: 1 cm 2 ) and described in Tables 1 to 4 on the stratum corneum side. 0.7 mL of each sample was added, and a physiological saline / ethanol (10: 1) solution was applied to the dermis layer side.
  • non-ergot anti dopamine D 2 transdermal preparation containing the receptor agonist and a manufacturing method thereof of the present invention it is possible to produce superior formulations of transdermal absorbability containing ropinirole and pramipexole It was. That is, it is an invention of a colloidal solution formulation in which fine micelles are formed in a water-polyhydric alcohol solvent by a combination of a hydrophobic solvent and a surfactant together with ropinirole or pramipexole. That is, by selecting and adjusting the pH of the colloidal solution, it can be prepared so that the side chain of ropinirole or pramipexole can easily come out on the surface of the micelle.
  • Ropinirole in such micelles has a high transdermal absorbability.
  • the hydrochloride can be used as it is, and the preparation of the preparation is easy.
  • the composition for transdermal use of the present invention is stable, has high safety to the skin and high skin permeability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention divulgue une spécialité pharmaceutique transdermique qui utilise des agonistes du récepteur D2 non ergotés antidopaminergiques comme les chlorhydrates de ropinirole ou les chlorhydrates de pramipexol. La spécialité pharmaceutique divulguée prend en compte la sécurité de la peau et la stabilité du médicament, montre une excellente perméabilité cutanée, et utilise des antagonistes du récepteur D2 non ergotés antidopaminergiques comme le ropinirole, qui sont actuellement utilisés comme préparations orales, d'une nouvelle manière comme agents transdermiques. La spécialité pharmaceutique transdermique divulguée est formée en combinant un agoniste du récepteur D2 non ergoté antidopaminergique avec un solvant hydrophobe et un tensioactif pour former une micelle minute dans un solvant d'eau et d'alcool polyhydrique, et ensuite en préparant une solution colloïdale contenant l'agoniste du récepteur D2 non ergoté antidopaminergique. En sélectionnant et en ajustant le pH de la solution colloïdale, les agonistes du récepteur D2 non ergotés antidopaminergiques font saillie à l'extérieur de la micelle, augmentant la capacité d'absorption transdermique et la perméabilité initiale des agonistes du récepteur D2 non ergotés antidopaminergiques.
PCT/JP2011/001381 2010-03-11 2011-03-09 Composition transdermique contenant un agent thérapeutique pour la maladie de parkinson WO2011111384A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010055152 2010-03-11
JP2010-055152 2010-03-11

Publications (1)

Publication Number Publication Date
WO2011111384A1 true WO2011111384A1 (fr) 2011-09-15

Family

ID=44563216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/001381 WO2011111384A1 (fr) 2010-03-11 2011-03-09 Composition transdermique contenant un agent thérapeutique pour la maladie de parkinson

Country Status (1)

Country Link
WO (1) WO2011111384A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015072564A1 (fr) 2013-11-17 2015-05-21 株式会社メドレックス Agent transdermique en solution colloïdale
WO2016186157A1 (fr) * 2015-05-19 2016-11-24 株式会社メドレックス Agent liquide à absorption par voie cutanée
EP3111935A4 (fr) * 2014-02-27 2017-03-15 Medrx Co., Ltd. Timbre transdermique contenant du pramipexole pour le traitement d'une maladie neurodégénérative
US11660344B2 (en) 2013-11-17 2023-05-30 Medrx Co., Ltd. Transdermal colloidal solution agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008108286A1 (fr) * 2007-03-02 2008-09-12 Teika Pharmaceutical Co., Ltd. Composition médicinale pour une absorption transdermique, unité de stockage de la composition médicinale et préparation par absorption transdermique utilisant celle-ci

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008108286A1 (fr) * 2007-03-02 2008-09-12 Teika Pharmaceutical Co., Ltd. Composition médicinale pour une absorption transdermique, unité de stockage de la composition médicinale et préparation par absorption transdermique utilisant celle-ci

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AZEEM A. ET AL.: "Nanocarrier for the transdermal delivery of an antiparkinsonian drug.", AAPS PHARMSCITECH, vol. 10, no. 4, 2009, pages 1093 - 1103 *
AZEEM A. ET AL.: "Nanoemulsion components screening and selection: a technical note.", AAPS PHARMSCITECH, vol. 10, no. 1, 2009, pages 69 - 76, XP055229545, DOI: doi:10.1208/s12249-008-9178-x *
BABOOTA S. ET AL.: "Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib.", ACTA PHARMACEUTICA, vol. 57, no. 3, 2007, pages 315 - 332, XP055045444, DOI: doi:10.2478/v10007-007-0025-5 *
DIXIT N. ET AL.: "Nanoemulsion system for the transdermal delivery of a poorly soluble cardiovascular drug.", PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, vol. 62, no. 1, 2008, pages 46 - 55 *
KUMAR D. ET AL.: "Investigation of a nanoemulsion as vehicle for transdermal delivery of amlodipine.", PHARMAZIE, vol. 64, no. 2, 2009, pages 80 - 85 *
SHAKEEL F. ET AL.: "Preparation and In Vivo Evaluation of Indomethacin Loaded True Nanoemulsions.", SCIENTIA PHARMACEUTICA, vol. 78, no. 1, November 2009 (2009-11-01), pages 47 - 56 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015072564A1 (fr) 2013-11-17 2015-05-21 株式会社メドレックス Agent transdermique en solution colloïdale
JPWO2015072564A1 (ja) * 2013-11-17 2017-03-16 株式会社 メドレックス 経皮吸収型コロイド液剤
US11660344B2 (en) 2013-11-17 2023-05-30 Medrx Co., Ltd. Transdermal colloidal solution agent
EP3111935A4 (fr) * 2014-02-27 2017-03-15 Medrx Co., Ltd. Timbre transdermique contenant du pramipexole pour le traitement d'une maladie neurodégénérative
US10045948B2 (en) 2014-02-27 2018-08-14 Medrx Co., Ltd. Pramipexole-containing transdermal patch for treatment of neurodegenerative disease
WO2016186157A1 (fr) * 2015-05-19 2016-11-24 株式会社メドレックス Agent liquide à absorption par voie cutanée

Similar Documents

Publication Publication Date Title
EP4252844A2 (fr) Compositions topiques et méthodes de traitement de maladies cutanés
US20240091192A1 (en) Dilutable formulations of cannabinoids and processes for their preparation
AU2017200329B2 (en) Sublingual apomorphine
KR101890317B1 (ko) 설하 필름
JP3903061B2 (ja) 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
EA014752B1 (ru) Способ и композиция для лечения ринита
JP2006524659A (ja) ケラチノサイトの過剰増殖、特に、アトピー性皮膚炎および乾癬を特徴とする疾患を治療するためのリルゾールの使用
WO2011111384A1 (fr) Composition transdermique contenant un agent thérapeutique pour la maladie de parkinson
EP3853204A1 (fr) Compositions pharmaceutiques d'aprémilast améliorées et stables
JP5816194B2 (ja) カルシポトリオール一水和物ナノクリスタル
EP3937915A1 (fr) Nouvelle nano-formulation de cannabidiol (cbd) et d'autres cannabinoïdes pour le traitement de maladies de la peau
US20210338549A1 (en) Compositions and methods for delivering cannabinoids to skin
EP2468270A1 (fr) Acide (R)-2-(3-fluoro-4-phénylphényl)propionique pour une utilisation dans le traitement de maladies cutanées
CN114452255A (zh) 一种阿戈美拉汀微乳、微乳凝胶及其制备方法
CN108904445A (zh) 钙泊三醇纳米悬浮液
CN114306233A (zh) 一种阿戈美拉汀自微乳制剂
WO2007086582A1 (fr) LOTION EN ÉMULSION DE TYPE HUILE DANS L'EAU CONTENANT DE LA 22-OXA-1α,25-DIHYDROXYVITAMINE D3 ET MÉTHODE DE TRAITEMENT D'UNE MALADIE CUTANÉE UTILISANT LADITE LOTION
JP4590224B2 (ja) トラニラストまたは薬理学的に許容される塩を含有する懸濁性医薬組成物
KR102462350B1 (ko) 이데베논 또는 이의 약학적으로 허용가능한 염을 함유하는 지질 비드 및 이의 제조방법
US20240299378A1 (en) Emulsion for use in the treatment of rosacea
WO2013111817A1 (fr) Composition crémeuse de type huile-dans-eau contenant du tacrolimus
CN117813117A (zh) 一种芦可替尼组合物及其用途
TW202241448A (zh) 含有依匹斯汀(epinastine)或其鹽及硫系抗氧化劑之經皮投與用醫藥組合物
CN118043052A (zh) 一种芦可替尼组合物及其制备方法
MXPA05006082A (es) Proceso para la estabilizacion quimica de un retinoide solubilizado en un solvente usando una base.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11753048

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11753048

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP